Stock AnalizIDEXX Laboratories Inc. IDXX
Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 1991 · data as of November 13, 2026
IDEXX Laboratories Inc. (IDXX) is a healthcare company listed in the US with a market value of about $55.5B. In the twelve months to September 30, 2026 it had revenue of $4.7B and net income of $1.2B, a net margin of 25.4%.
Its overall Stock Analiz score is 3.4 out of 5 (good). The strongest part is track record (5/5); the weakest is value (0/5).
Key numbers: a P/E of 47.5, a price to free cash flow of 42.6, 5-year revenue growth of 10% a year, a 5-year average ROIC of 44%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 63% below the current price.
Score: 3.4 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Pays a dividend
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.7B | $4.3B | $3.9B | $3.7B | $3.4B | $3.2B | $2.7B | $2.4B | $2.2B | $2.0B | $1.8B |
| Net income | $1.2B | $1.1B | $888M | $845M | $679M | $745M | $582M | $428M | $377M | $263M | $222M |
| Free cash flow | $1.3B | $1.1B | $808M | $773M | $394M | $636M | $541M | $304M | $284M | $299M | $274M |
| EPS (diluted) | $14.84 | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 | $6.71 | $4.89 | $4.26 | $2.94 | $2.44 |
| Net margin | 25.4% | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% | 17.8% | 17.0% | 13.4% | 12.5% |
| ROIC | — | 49.8% | 38.7% | 38.0% | 47.3% | 46.7% | 37.3% | 47.2% | 40.8% | 23.6% | 22.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $717.17, 2% above the current price; targets range from $470.00 to $810.00; the consensus rating is “Buy”; expected EPS is $15.00 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is IDEXX Laboratories’s P/E ratio?
About 47.5, based on the last twelve months of diluted earnings per share (forward P/E about 44.8).
Is IDEXX Laboratories stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 63% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does IDEXX Laboratories pay a dividend?
Not currently.
Is IDEXX Laboratories a good stock to buy?
We do not give buy or sell advice. IDEXX Laboratories scores 3.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.